CHICAGO, IL / ACCESSWIRE / September 15, 2022 / Cosmos Holdings d/b/a Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), is a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that the Company's proprietary line of nutraceuticals, Sky Premium Life, has entered into an exclusive agreement with Mediprovita GbR. Mediprovita will begin selling its Sky Premium Life ("SPL") products in Germany and Austria beginning in the Fourth Quarter. The initial order for 20 SKUs will be sold through Amazon, Ebay, and Mediprovita's own ecommerce website. The Company expects to extend its relationship with Mediprovita in the near future to include the distribution of 70 SKU's.
Mediprovita is a full-service distributor and logistics provider of consumer products with over 30 years of experience. Cosmos has signed a distribution agreement with Mediprovita to be their exclusive distributor in Germany and Austria of the Sky Premium Life line. A proprietary, luxury and high-quality nutritional supplements' brand, with a complete range of vitamins, minerals, herbs, and unique formulas. Under the terms of the agreement, Mediprovita will employ its sales, marketing, and e-commerce expertise to distribute Sky Premium Life products throughout Germany and Austria. Aggelos Kiriazis, Mediprovita's CEO stated "Sky Premium Life products are a great fit for our business, as we began selling food supplements two years ago, with great success. Based on our comprehensive market research, we expect SPL products to have strong rate of acceptance in the German and Austrian markets."
"Our entry into Germany and Austria is an important step for us, as Germany has the largest Nutraceuticals market in Europe." stated Greg Siokas, Chief Executive Officer of Cosmos Health. "We are continuing our global roll-out strategy as we launch our products worldwide. Thus far in 2022, we have successfully introduced our products on Amazon in the United States, United Kingdom, Canada, and Singapore. Our key objective remains to grow internationally, as we continue to leverage our robust global logistics and distribution capabilities, while expanding our customer base worldwide."
According to Mordor Intelligence, the European nutraceutical market is expected to grow at a 7.5% CAGR to surpass $100 billion by 2027. Germany boasts the largest nutraceutical market within Europe at roughly 14%. Market expansion in Europe is attributed to the continued rising healthcare costs and an aging population.
About Cosmos Health, Inc.
Cosmos Health Inc. (Nasdaq:COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation." Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmosholdingsinc.com and www.skypremiumlife.com.
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Lytham Partners, LLC
E: [email protected]
SOURCE: Cosmos Holdings, Inc.